Active substances
Acetylsalicylic acid + Caffeine
- SFDA 3
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ANACIN 398MG TAB | 398, 22.7 mg | Tablet · Oral use | 30 Blister | SAR 4.00 | NCE · OTC | WHITEHALL LABORATORIES | Withdrawn by MAH · Not Marketed |
| ASKINE TAB | 490, 10 mg | Tablet · Oral use | 30 Blister | SAR 3.75 | NCE · OTC | ALEXANDRIA CO. | Withdrawn by regulatory authority · Not Marketed |
| ASPINOL | 350 ,15 mg | Tablet · Oral use | 20 Blister | SAR 1.55 | Generic · Prescription | PHARCO PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Aspirin 325mg / Caffeine 15mg tablets | £0.94 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aspirin 325mg / Caffeine 15mg tablets | £1.20 | 16 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.